(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2012 (20.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/125559 A1

(51) International Patent Classification:
C07K 16/36 (2006.01)

(21) International Application Number:
PCT/US2012/028770

(22) International Filing Date:
12 March 2012 (12.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/452,674 15 March 2011 (15.03.2011) US

(71) Applicant *(for all designated States except US)*: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALMAGRO, Juan, Carlos** [US/US]; 44 Harvard Ave. 35, Brookline, MA 02446 (US). **ANDERSON, Glenn, Mark** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **CHI, Ellen** [US/US]; 3210 Merryfield Row, San Diego, CA 92121 (US). **MARTINEZ, Christian** [PH/US]; 3210 Merryfield Row, San Diego, CA 92121 (US). **RAGHUNATHAN, Gopalan** [US/US]; 12620 Creekwood Court, San Diego, CA 92129 (US). **SWANSON, Ronald** [US/US]; 3210 Merryfield Row, San Diego, CA 92121 (US). **TEPLYAKOV, Alexey** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **TSE, Kam-fai** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **WU, Sheng-jium** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **ZHOU, Hong, Mimi** [US/US]; 3210 Merryfield Row, San Diego, CA 92121 (US).

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, One Johnson& Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,

[Continued on next page]

(54) Title: HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF

(57) Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.




Fig. 1

WO 2012/125559 A1

SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*